Baillie Gifford European Growth Trust Reports Challenging H1 Amid Strategic Tender Offer
Baillie Gifford European Growth Trust's H1 NAV fell 6.7% vs +3.5% benchmark. 2028 tender offer & 8.6% discount hint at rebound potential. Insights here.
This article covers information on Baillie Gifford European Growth Tst.
LON:BGEURough Seas in European Growth Waters
Baillie Gifford European Growth Trust’s first-half report reads like a thriller novel where the protagonist spends 200 pages getting punched in the face. A -6.7% NAV tumble against a +3.5% benchmark rise? Ouch. But as any seasoned investor knows, it’s the third act redemption arc that matters – and this trust is betting big on a comeback story.
The Numbers That Matter
- NAV Total Return: -6.7% (Benchmark: +3.5%)
- Assets Under Management: £378.1m (-9% since Sept 2024)
- Discount Narrowing: 15.6% → 8.6% (Thank £9.6m in buybacks)
- Trump Tariff Tango: 15% US sales exposure vs 22% benchmark
Portfolio Pain Points & Bright Spots
The ‘Three Horsemen of Underperformance’ – Hypoport (German mortgages), Nexans (wind cables), and Soitec (silicon wafers) – are all caught in cyclical crosswinds. Yet managers argue these are operational stalwarts simply waiting for macroeconomic winds to shift.
The Italian Stallion
Enter Bending Spoons – the Milanese software house quietly building an empire of AI-powered apps. This 4.5% private holding (+£17m valuation) exemplifies Baillie Gifford’s conviction: “Profitable, asset-light, and about as competitive as Messi in a pub league.”
Strategic Chess Moves
While selling six positions (including CRISPR Therapeutics’ gene-editing gambles), the team placed three intriguing bets:
- ASM International: The ‘other’ Dutch chip play – think atomic layer deposition, not ASML’s lithography
- Edenred: Meal voucher maestro trading at 2010 valuations after Brazil scare
- Röko: Swedish acquisition roll-up with Lifco’s playbook and 5x growth runway
The £327m Question: To Tender or Not?
That looming 2028 performance-linked tender offer adds spice to the narrative. Fail to beat the benchmark, and shareholders get an exit near NAV. It’s a bold move that says: “We’ll put skin in the game, but European growth stocks need time to marinate.”
Silver Linings Playbook
Despite the storm clouds, three rays of sunlight pierce through:
- European GDP catching up to US (Germany’s green/defence spending surge)
- Tech platforms like Spotify demonstrating pricing power amidst tariff chaos
- Structural growth stories in semiconductors, biologics, and building materials
Bottom Line for Investors
This isn’t a ‘set and forget’ trust. The -8.6% discount whispers opportunity, but requires conviction in:
- Europe’s rearmament/energy transition creating new champions
- Growth-style resurgence after value’s recent dominance
- Baillie Gifford’s stock-picking chops to justify 0.55% fees
As Chairman Barron diplomatically notes: “You make most of your money in bear markets – you just don’t realise it at the time.” Whether this proves prescient or Pollyannaish depends on Europe’s ability to dance through the Trumpian trade war minefield. One to watch with both optimism and a tightly set stop-loss.
Related
Keep reading
Investing
Ten Technologies Preliminary Results 2026: Record EBITDA and Member Growth
Ten Technologies delivered record 2026 results as active members rose 23% and adjusted EBITDA increased 10% to £16.1 million.
JoshuaNovember 11, 2026
Investing
Winvia Entertainment completes The Online Giveaway Guys acquisition
Winvia Entertainment has completed its purchase of The Online Giveaway Guys' business and key assets, excluding liabilities, cash and receivables.
JoshuaNovember 10, 2026
Investing
RUA Life Sciences reaches positive adjusted EBITDA as Structural Heart spin-out reshapes the group
RUA Life Sciences expects £5.5 million revenue and £0.3 million adjusted EBITDA, but ABISS weakness and lower cash warrant attention.
JoshuaNovember 9, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.